drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00719 | DB06700 | 1,219 | 643 | [
"DDInter149",
"DDInter511"
] | Azatadine | Desvenlafaxine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of ad... | Moderate | 1 | [
[
[
1219,
24,
643
]
],
[
[
1219,
63,
1100
],
[
1100,
1,
643
]
],
[
[
1219,
6,
8374
],
[
8374,
45,
643
]
],
[
[
1219,
24,
1311
],
[
1311,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Desvenlafaxine (Compound)
Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Desvenlafaxine (Compound)
Azatadine may cause a moderate interaction that could exac... |
DB01024 | DB09154 | 1,096 | 1,475 | [
"DDInter1252",
"DDInter1686"
] | Mycophenolic acid | Sodium citrate | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Moderate | 1 | [
[
[
1096,
24,
1475
]
],
[
[
1096,
63,
954
],
[
954,
23,
1475
]
],
[
[
1096,
63,
1467
],
[
1467,
24,
1475
]
],
[
[
1096,
24,
1024
],
[
1024... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium citrate"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril... | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Enoxaci... |
DB00367 | DB08907 | 566 | 1,344 | [
"DDInter1061",
"DDInter280"
] | Levonorgestrel | Canagliflozin | Levonorgestrel (LNG) is a synthetic progestogen similar to [Progesterone] used in contraception and hormone therapy.[A181988,T659] Also known as Plan B, it is used as a single agent in emergency contraception, and as a hormonal contraceptive released from an intrauterine device, commonly referred to as an IUD. Some of ... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
566,
24,
1344
]
],
[
[
566,
24,
549
],
[
549,
1,
1344
]
],
[
[
566,
6,
8374
],
[
8374,
45,
1344
]
],
[
[
566,
21,
28681
],
[
28681,
... | [
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Levonorgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
... | Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Levonorgestrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound)
Levonorgestrel (Compound) causes Hypersensitiv... |
DB00804 | DB01227 | 1,507 | 1,301 | [
"DDInter543",
"DDInter1043"
] | Dicyclomine | Levacetylmethadol | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Moderate | 1 | [
[
[
1507,
24,
1301
]
],
[
[
1507,
63,
494
],
[
494,
1,
1301
]
],
[
[
1507,
24,
1511
],
[
1511,
63,
1301
]
],
[
[
1507,
24,
358
],
[
358,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Levacetylmethadol (Compound)
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interac... |
DB06589 | DB10429 | 1,250 | 200 | [
"DDInter1400",
"DDInter282"
] | Pazopanib | Candida albicans | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
1250,
24,
200
]
],
[
[
1250,
63,
1683
],
[
1683,
24,
200
]
],
[
[
1250,
25,
976
],
[
976,
24,
200
]
],
[
[
1250,
24,
594
],
[
594,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Pazopanib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib ma... |
DB08918 | DB09054 | 41 | 384 | [
"DDInter1059",
"DDInter905"
] | Levomilnacipran | Idelalisib | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interc... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
41,
25,
384
]
],
[
[
41,
64,
222
],
[
222,
23,
384
]
],
[
[
41,
63,
1618
],
[
1618,
24,
384
]
],
[
[
41,
24,
659
],
[
659,
63,
... | [
[
[
"Levomilnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Levomilnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
... | Levomilnacipran may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozanti... |
DB00771 | DB00986 | 262 | 1,192 | [
"DDInter397",
"DDInter834"
] | Clidinium | Glycopyrronium | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Moderate | 1 | [
[
[
262,
24,
1192
]
],
[
[
262,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
262,
6,
2720
],
[
2720,
45,
1192
]
],
[
[
262,
62,
1014
],
[
1014,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Clidinium (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Glycopyrronium (Compound)
Clidinium ma... |
DB00472 | DB01362 | 758 | 497 | [
"DDInter758",
"DDInter960"
] | Fluoxetine | Iohexol | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
758,
25,
497
]
],
[
[
758,
21,
28681
],
[
28681,
60,
497
]
],
[
[
758,
24,
1574
],
[
1574,
63,
497
]
],
[
[
758,
63,
999
],
[
999,
... | [
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Fluoxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused b... | Fluoxetine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Urea and Urea may cause a moderate interaction that could exacerbate diseases when taken with Iohexol
... |
DB04896 | DB09082 | 901 | 659 | [
"DDInter1220",
"DDInter1934"
] | Milnacipran | Vilanterol | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
901,
24,
659
]
],
[
[
901,
64,
222
],
[
222,
24,
659
]
],
[
[
901,
63,
702
],
[
702,
24,
659
]
],
[
[
901,
24,
1618
],
[
1618,
2... | [
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Milnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutra... | Milnacipran may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may ca... |
DB01082 | DB01357 | 1,448 | 890 | [
"DDInter1713",
"DDInter1160"
] | Streptomycin | Mestranol | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | The 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives. | Moderate | 1 | [
[
[
1448,
24,
890
]
],
[
[
1448,
63,
1438
],
[
1438,
1,
890
]
],
[
[
1448,
63,
50
],
[
50,
24,
890
]
],
[
[
1448,
35,
416
],
[
416,
... | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
]
],
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
... | Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol (Compound) resembles Mestranol (Compound)
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine may cause a moderate interaction tha... |
DB01064 | DB01579 | 1,148 | 341 | [
"DDInter987",
"DDInter1439"
] | Isoprenaline | Phendimetrazine | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Phendimetrazine is a weight loss medication. Phendimetrazine is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances and in the US since 1970. | Moderate | 1 | [
[
[
1148,
24,
341
]
],
[
[
1148,
21,
28662
],
[
28662,
60,
341
]
],
[
[
1148,
24,
959
],
[
959,
24,
341
]
],
[
[
1148,
24,
1281
],
[
1281,... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phendimetrazine"
]
],
[
[
"Isoprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is c... | Isoprenaline (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Phendimetrazine (Compound)
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Phendi... |
DB00163 | DB00851 | 1,461 | 611 | [
"DDInter1943",
"DDInter463"
] | Vitamin E | Dacarbazine | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Moderate | 1 | [
[
[
1461,
24,
611
]
],
[
[
1461,
24,
141
],
[
141,
24,
611
]
],
[
[
1461,
62,
66
],
[
66,
24,
611
]
],
[
[
1461,
23,
1531
],
[
1531,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Efalizumab and Efalizu... |
DB06210 | DB11730 | 72 | 351 | [
"DDInter631",
"DDInter1588"
] | Eltrombopag | Ribociclib | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
72,
24,
351
]
],
[
[
72,
24,
466
],
[
466,
62,
351
]
],
[
[
72,
24,
1627
],
[
1627,
23,
351
]
],
[
[
72,
63,
372
],
[
372,
24,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and C... |
DB10315 | DB11569 | 1,137 | 1,093 | [
"DDInter1127",
"DDInter1003"
] | Measles virus vaccine live attenuated | Ixekizumab | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Major | 2 | [
[
[
1137,
25,
1093
]
],
[
[
1137,
64,
66
],
[
66,
24,
1093
]
],
[
[
1137,
25,
270
],
[
270,
63,
1093
]
],
[
[
1137,
64,
1057
],
[
1057,
... | [
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Efa... | Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken wi... |
DB00662 | DB08815 | 717 | 154 | [
"DDInter1873",
"DDInter1104"
] | Trimethobenzamide | Lurasidone | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
717,
24,
154
]
],
[
[
717,
21,
28921
],
[
28921,
60,
154
]
],
[
[
717,
24,
1532
],
[
1532,
24,
154
]
],
[
[
717,
63,
1242
],
[
1242,
... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Trimethobenzamide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side E... | Trimethobenzamide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Lurasidone (Compound)
Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when take... |
DB01069 | DB04953 | 401 | 495 | [
"DDInter1533",
"DDInter708"
] | Promethazine | Ezogabine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Moderate | 1 | [
[
[
401,
24,
495
]
],
[
[
401,
21,
28787
],
[
28787,
60,
495
]
],
[
[
401,
62,
112
],
[
112,
23,
495
]
],
[
[
401,
63,
1494
],
[
1494,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ezogabine"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is... | Promethazine (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ezogabine (Compound)
Promethazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with ... |
DB00450 | DB00539 | 78 | 11 | [
"DDInter603",
"DDInter1837"
] | Droperidol | Toremifene | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as ... | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Major | 2 | [
[
[
78,
25,
11
]
],
[
[
78,
63,
1594
],
[
1594,
40,
11
]
],
[
[
78,
24,
1376
],
[
1376,
40,
11
]
],
[
[
78,
21,
28921
],
[
28921,
60... | [
[
[
"Droperidol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine... | Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Toremifene (Compound)
Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Toremifene (... |
DB00315 | DB00358 | 767 | 1,010 | [
"DDInter1969",
"DDInter1140"
] | Zolmitriptan | Mefloquine | Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)<sub>1B/1D/(1F)</sub> receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptan... | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Moderate | 1 | [
[
[
767,
24,
1010
]
],
[
[
767,
21,
28789
],
[
28789,
60,
1010
]
],
[
[
767,
25,
1494
],
[
1494,
63,
1010
]
],
[
[
767,
24,
1619
],
[
1619... | [
[
[
"Zolmitriptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
]
],
[
[
"Zolmitriptan",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
... | Zolmitriptan (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Mefloquine (Compound)
Zolmitriptan may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when t... |
DB09038 | DB12015 | 1,450 | 1,033 | [
"DDInter636",
"DDInter53"
] | Empagliflozin | Alpelisib | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1450,
24,
1033
]
],
[
[
1450,
63,
1254
],
[
1254,
24,
1033
]
],
[
[
1450,
24,
1612
],
[
1612,
24,
1033
]
],
[
[
1450,
24,
1017
],
[
10... | [
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
... | Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Fo... |
DB00526 | DB01073 | 1,555 | 1,488 | [
"DDInter1355",
"DDInter745"
] | Oxaliplatin | Fludarabine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Moderate | 1 | [
[
[
1555,
24,
1488
]
],
[
[
1555,
24,
1585
],
[
1585,
1,
1488
]
],
[
[
1555,
64,
839
],
[
839,
23,
1488
]
],
[
[
1555,
24,
1539
],
[
1539,... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
],
[
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Adenosine and Adenosine (Compound) resembles Fludarabine (Compound)
Oxaliplatin may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinic... |
DB00283 | DB06077 | 701 | 879 | [
"DDInter395",
"DDInter1102"
] | Clemastine | Lumateperone | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
701,
24,
879
]
],
[
[
701,
24,
407
],
[
407,
63,
879
]
],
[
[
701,
35,
1511
],
[
1511,
24,
879
]
],
[
[
701,
24,
537
],
[
537,
2... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Clemastine (Compound) resembles Mepenzolate (Compound) and Clemastine may cause a moderate interaction that could exacer... |
DB00364 | DB00682 | 417 | 126 | [
"DDInter1717",
"DDInter1951"
] | Sucralfate | Warfarin | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
417,
24,
126
]
],
[
[
417,
63,
362
],
[
362,
24,
126
]
],
[
[
417,
6,
1829
],
[
1829,
45,
126
]
],
[
[
417,
24,
135
],
[
135,
62... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Sucralfate (Compound) binds ALB (Gene) and ALB (Gene) is bound by Warfarin (Compound)
Sucralfate may cause a moderat... |
DB08904 | DB11569 | 375 | 1,093 | [
"DDInter342",
"DDInter1003"
] | Certolizumab pegol | Ixekizumab | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Major | 2 | [
[
[
375,
25,
1093
]
],
[
[
375,
23,
1114
],
[
1114,
23,
1093
]
],
[
[
375,
62,
1461
],
[
1461,
23,
1093
]
],
[
[
375,
63,
608
],
[
608,
... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
... | Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Vitamin... |
DB00983 | DB08899 | 480 | 129 | [
"DDInter776",
"DDInter649"
] | Formoterol | Enzalutamide | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
480,
24,
129
]
],
[
[
480,
24,
918
],
[
918,
1,
129
]
],
[
[
480,
6,
12523
],
[
12523,
45,
129
]
],
[
[
480,
21,
28703
],
[
28703,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Formoterol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Enzalutamide (Compound)
Formoterol (Compound) causes Pruritus (Side Effect) and Pr... |
DB00916 | DB00995 | 112 | 1,112 | [
"DDInter1202",
"DDInter139"
] | Metronidazole | Auranofin | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Auranofin is a gold salt that is capable of eliciting pharmacologic actions that suppress inflammation and stimulate cell-mediated immunity. It has subsequently been listed by the World Health Organization as a member of the antirheumatic agent category. Auranofin appears to induce heme oxygenase 1 (HO-1) mRNA. Heme ox... | Moderate | 1 | [
[
[
112,
24,
1112
]
],
[
[
112,
21,
28757
],
[
28757,
60,
1112
]
],
[
[
112,
24,
36
],
[
36,
63,
1112
]
],
[
[
112,
63,
134
],
[
134,
... | [
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Auranofin"
]
],
[
[
"Metronidazole",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is... | Metronidazole (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Auranofin (Compound)
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Aurano... |
DB00731 | DB01268 | 1,144 | 1,151 | [
"DDInter1269",
"DDInter1731"
] | Nateglinide | Sunitinib | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally av... | Moderate | 1 | [
[
[
1144,
24,
1151
]
],
[
[
1144,
6,
6799
],
[
6799,
45,
1151
]
],
[
[
1144,
21,
28680
],
[
28680,
60,
1151
]
],
[
[
1144,
24,
1247
],
[
1... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compound)"... | Nateglinide (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Sunitinib (Compound)
Nateglinide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Sunitinib (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfame... |
DB00046 | DB00861 | 1,179 | 914 | [
"DDInter940",
"DDInter551"
] | Insulin lispro | Diflunisal | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Moderate | 1 | [
[
[
1179,
24,
914
]
],
[
[
1179,
24,
417
],
[
417,
23,
914
]
],
[
[
1179,
24,
1019
],
[
1019,
63,
914
]
],
[
[
1179,
24,
251
],
[
251,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Diflunisal
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and... |
DB00448 | DB11791 | 1,215 | 785 | [
"DDInter1022",
"DDInter287"
] | Lansoprazole | Capmatinib | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Minor | 0 | [
[
[
1215,
23,
785
]
],
[
[
1215,
40,
837
],
[
837,
23,
785
]
],
[
[
1215,
63,
1324
],
[
1324,
24,
785
]
],
[
[
1215,
24,
98
],
[
98,
... | [
[
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capmatinib"
]
],
[
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a m... | Lansoprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Capmatinib
Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction ... |
DB00414 | DB00477 | 590 | 216 | [
"DDInter16",
"DDInter363"
] | Acetohexamide | Chlorpromazine | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
590,
24,
216
]
],
[
[
590,
24,
1178
],
[
1178,
1,
216
]
],
[
[
590,
24,
684
],
[
684,
40,
216
]
],
[
[
590,
24,
1283
],
[
1283,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resemble... |
DB00983 | DB06595 | 480 | 1,491 | [
"DDInter776",
"DDInter1214"
] | Formoterol | Midostaurin | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
480,
24,
1491
]
],
[
[
480,
24,
761
],
[
761,
24,
1491
]
],
[
[
480,
63,
888
],
[
888,
24,
1491
]
],
[
[
480,
24,
927
],
[
927,
... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
... | Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamo... |
DB06691 | DB14575 | 849 | 733 | [
"DDInter1155",
"DDInter674"
] | Mepyramine | Eslicarbazepine | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
849,
24,
733
]
],
[
[
849,
63,
1264
],
[
1264,
24,
733
]
],
[
[
849,
24,
1609
],
[
1609,
24,
733
]
],
[
[
849,
74,
662
],
[
662,
... | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Eslicarbazepine
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pent... |
DB00581 | DB14568 | 355 | 982 | [
"DDInter1018",
"DDInter1000"
] | Lactulose | Ivosidenib | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
355,
24,
982
]
],
[
[
355,
24,
28
],
[
28,
24,
982
]
],
[
[
355,
23,
286
],
[
286,
24,
982
]
],
[
[
355,
63,
472
],
[
472,
25,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Lactulose may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Mag... |
DB00748 | DB06702 | 662 | 573 | [
"DDInter297",
"DDInter731"
] | Carbinoxamine | Fesoterodine | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
662,
24,
573
]
],
[
[
662,
24,
211
],
[
211,
1,
573
]
],
[
[
662,
63,
494
],
[
494,
1,
573
]
],
[
[
662,
6,
12523
],
[
12523,
45... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],... | Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Fesotero... |
DB00059 | DB09078 | 1,560 | 1,228 | [
"DDInter1404",
"DDInter1036"
] | Pegaspargase | Lenvatinib | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
1560,
24,
1228
]
],
[
[
1560,
24,
463
],
[
463,
23,
1228
]
],
[
[
1560,
24,
609
],
[
609,
24,
1228
]
],
[
[
1560,
25,
770
],
[
770,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
],
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and ... |
DB00651 | DB00690 | 746 | 1,216 | [
"DDInter613",
"DDInter762"
] | Dyphylline | Flurazepam | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | A benzodiazepine derivative used mainly as a hypnotic. | Minor | 0 | [
[
[
746,
23,
1216
]
],
[
[
746,
23,
1418
],
[
1418,
1,
1216
]
],
[
[
746,
23,
481
],
[
481,
40,
1216
]
],
[
[
746,
62,
902
],
[
902,
... | [
[
[
"Dyphylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flurazepam"
]
],
[
[
"Dyphylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Estazolam"
],
[
"... | Dyphylline may cause a minor interaction that can limit clinical effects when taken with Estazolam and Estazolam (Compound) resembles Flurazepam (Compound)
Dyphylline may cause a minor interaction that can limit clinical effects when taken with Quazepam and Quazepam (Compound) resembles Flurazepam (Compound)
Dyphylline... |
DB00279 | DB00641 | 1,152 | 467 | [
"DDInter1074",
"DDInter1675"
] | Liothyronine | Simvastatin | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Minor | 0 | [
[
[
1152,
23,
467
]
],
[
[
1152,
6,
6648
],
[
6648,
45,
467
]
],
[
[
1152,
7,
8155
],
[
8155,
46,
467
]
],
[
[
1152,
21,
28882
],
[
28882,... | [
[
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Simvastatin"
]
],
[
[
"Liothyronine",
"{u} (Compound) binds {v} (Gene)",
"SLCO1A2"
],
[
"SLCO1A2",
"{u} (Gene) is bound by {v} (Compou... | Liothyronine (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Simvastatin (Compound)
Liothyronine (Compound) upregulates ABCC5 (Gene) and ABCC5 (Gene) is upregulated by Simvastatin (Compound)
Liothyronine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effec... |
DB00055 | DB00407 | 834 | 202 | [
"DDInter605",
"DDInter115"
] | Drotrecogin alfa | Ardeparin | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Major | 2 | [
[
[
834,
25,
202
]
],
[
[
834,
24,
116
],
[
116,
63,
202
]
],
[
[
834,
25,
1496
],
[
1496,
63,
202
]
],
[
[
834,
25,
1564
],
[
1564,
... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ardeparin"
]
],
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
],
[
... | Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Ardeparin
Drotrecogin alfa may lead to a major life threatening interaction when taken with Nintedanib and Ninted... |
DB04843 | DB08897 | 1,511 | 1,429 | [
"DDInter1149",
"DDInter22"
] | Mepenzolate | Aclidinium | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
1511,
24,
1429
]
],
[
[
1511,
63,
352
],
[
352,
24,
1429
]
],
[
[
1511,
6,
4304
],
[
4304,
45,
1429
]
],
[
[
1511,
54,
19248
],
[
1924... | [
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
... | Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Mepenzolate (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Aclidinium (Compound)
Mepenzolate (Compound)... |
DB00545 | DB01082 | 751 | 1,448 | [
"DDInter1548",
"DDInter1713"
] | Pyridostigmine | Streptomycin | Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in muscle tone loss, muscle weakness, and fatigue. Acetylcholinesterase inhibitors have been the symptomatic treatment of ... | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Moderate | 1 | [
[
[
751,
24,
1448
]
],
[
[
751,
21,
28680
],
[
28680,
60,
1448
]
],
[
[
751,
24,
361
],
[
361,
24,
1448
]
],
[
[
751,
40,
1372
],
[
1372,
... | [
[
[
"Pyridostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
]
],
[
[
"Pyridostigmine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caus... | Pyridostigmine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Streptomycin (Compound)
Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Neomycin and Neomycin may cause a moderate interaction that could exacerbate diseases when taken with Streptomyci... |
DB00197 | DB01058 | 1,324 | 978 | [
"DDInter1881",
"DDInter1510"
] | Troglitazone | Praziquantel | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum. Specifically, it is known as a treatment of trematodes and cestodes infections such as schistosomiasis, taeniasis, and cysticercosis. The efficacy of praziquantel in treating parasitic flatworms infecti... | Moderate | 1 | [
[
[
1324,
24,
978
]
],
[
[
1324,
24,
1623
],
[
1623,
63,
978
]
],
[
[
1324,
24,
152
],
[
152,
24,
978
]
],
[
[
1324,
23,
1101
],
[
1101,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Praziquantel"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium and Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Praziquantel
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bosen... |
DB00363 | DB00514 | 695 | 506 | [
"DDInter419",
"DDInter527"
] | Clozapine | Dextromethorphan | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Moderate | 1 | [
[
[
695,
24,
506
]
],
[
[
695,
6,
8374
],
[
8374,
45,
506
]
],
[
[
695,
24,
741
],
[
741,
63,
506
]
],
[
[
695,
63,
1324
],
[
1324,
... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Clozapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dextromethorphan (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan
Clozapin... |
DB00465 | DB05578 | 886 | 330 | [
"DDInter1010",
"DDInter1566"
] | Ketorolac | Ramucirumab | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
886,
25,
330
]
],
[
[
886,
24,
384
],
[
384,
63,
330
]
],
[
[
886,
1,
282
],
[
282,
63,
330
]
],
[
[
886,
24,
222
],
[
222,
24,
... | [
[
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib"... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Ketorolac (Compound) resembles Nepafenac (Compound) and Nepafenac may cause a moderate interaction that could ex... |
DB01021 | DB01069 | 674 | 401 | [
"DDInter1861",
"DDInter1533"
] | Trichlormethiazide | Promethazine | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
674,
24,
401
]
],
[
[
674,
24,
1264
],
[
1264,
63,
401
]
],
[
[
674,
24,
286
],
[
286,
62,
401
]
],
[
[
674,
63,
1614
],
[
1614,
... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
... | Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium... |
DB00465 | DB01067 | 886 | 959 | [
"DDInter1010",
"DDInter826"
] | Ketorolac | Glipizide | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, men... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
886,
24,
959
]
],
[
[
886,
63,
245
],
[
245,
40,
959
]
],
[
[
886,
24,
1411
],
[
1411,
1,
959
]
],
[
[
886,
18,
7247
],
[
7247,
... | [
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Ketorolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Ketorolac may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound)
... |
DB00631 | DB09570 | 372 | 1,480 | [
"DDInter405",
"DDInter1002"
] | Clofarabine | Ixazomib | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
372,
24,
1480
]
],
[
[
372,
24,
987
],
[
987,
63,
1480
]
],
[
[
372,
63,
440
],
[
440,
24,
1480
]
],
[
[
372,
24,
248
],
[
248,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR... | Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Clofarabine may cause a moderate intera... |
DB00222 | DB00808 | 245 | 1,605 | [
"DDInter825",
"DDInter916"
] | Glimepiride | Indapamide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Moderate | 1 | [
[
[
245,
24,
1605
]
],
[
[
245,
24,
811
],
[
811,
1,
1605
]
],
[
[
245,
21,
28826
],
[
28826,
60,
1605
]
],
[
[
245,
24,
126
],
[
126,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Glimepiride (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Indapamide (Compound)
Glimepiride may cause a moderate interaction... |
DB00396 | DB01067 | 989 | 959 | [
"DDInter1529",
"DDInter826"
] | Progesterone | Glipizide | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
989,
24,
959
]
],
[
[
989,
63,
245
],
[
245,
40,
959
]
],
[
[
989,
24,
1411
],
[
1411,
1,
959
]
],
[
[
989,
6,
8374
],
[
8374,
4... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Comp... |
DB09564 | DB11071 | 1,296 | 1,004 | [
"DDInter930",
"DDInter1449"
] | Insulin degludec | Phenyl salicylate | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in ). Phenyl salicylate ma... | Moderate | 1 | [
[
[
1296,
24,
1004
]
],
[
[
1296,
63,
1411
],
[
1411,
24,
1004
]
],
[
[
1296,
24,
877
],
[
877,
63,
1004
]
],
[
[
1296,
63,
1411
],
[
1411... | [
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutam... | Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00055 | DB00814 | 834 | 1,171 | [
"DDInter605",
"DDInter1143"
] | Drotrecogin alfa | Meloxicam | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Major | 2 | [
[
[
834,
25,
1171
]
],
[
[
834,
25,
1027
],
[
1027,
40,
1171
]
],
[
[
834,
25,
936
],
[
936,
63,
1171
]
],
[
[
834,
25,
366
],
[
366,
... | [
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Meloxicam"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Piroxicam"
],
[
"Piroxicam",
... | Drotrecogin alfa may lead to a major life threatening interaction when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Drotrecogin alfa may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate diseases wh... |
DB00013 | DB01105 | 1,255 | 222 | [
"DDInter1905",
"DDInter1665"
] | Urokinase | Sibutramine | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1255,
24,
222
]
],
[
[
1255,
25,
1046
],
[
1046,
63,
222
]
],
[
[
1255,
24,
1027
],
[
1027,
24,
222
]
],
[
[
1255,
25,
1432
],
[
1432,... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Caplacizu... | Urokinase may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam may cause... |
DB00202 | DB00798 | 190 | 1,132 | [
"DDInter1716",
"DDInter815"
] | Succinylcholine | Gentamicin | Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and su... | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | Major | 2 | [
[
[
190,
25,
1132
]
],
[
[
190,
21,
29339
],
[
29339,
60,
1132
]
],
[
[
190,
24,
608
],
[
608,
23,
1132
]
],
[
[
190,
25,
361
],
[
361,
... | [
[
[
"Succinylcholine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gentamicin"
]
],
[
[
"Succinylcholine",
"{u} (Compound) causes {v} (Side Effect)",
"Respiratory depression"
],
[
"Respiratory depression",
"{u} ... | Succinylcholine (Compound) causes Respiratory depression (Side Effect) and Respiratory depression (Side Effect) is caused by Gentamicin (Compound)
Succinylcholine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical... |
DB00515 | DB00853 | 589 | 1,686 | [
"DDInter387",
"DDInter1762"
] | Cisplatin | Temozolomide | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Moderate | 1 | [
[
[
589,
24,
1686
]
],
[
[
589,
21,
28996
],
[
28996,
60,
1686
]
],
[
[
589,
23,
945
],
[
945,
62,
1686
]
],
[
[
589,
62,
1467
],
[
1467,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Cisplatin",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal discomfort"
],
[
"Musculoskeletal discomfort"... | Cisplatin (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Temozolomide (Compound)
Cisplatin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinic... |
DB01004 | DB12332 | 563 | 1,619 | [
"DDInter806",
"DDInter1626"
] | Ganciclovir | Rucaparib | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
563,
24,
1619
]
],
[
[
563,
24,
309
],
[
309,
24,
1619
]
],
[
[
563,
63,
1419
],
[
1419,
24,
1619
]
],
[
[
563,
1,
248
],
[
248,
... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
... | Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imati... |
DB00598 | DB09481 | 1,523 | 460 | [
"DDInter1013",
"DDInter1113"
] | Labetalol | Magnesium carbonate | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Minor | 0 | [
[
[
1523,
23,
460
]
],
[
[
1523,
24,
401
],
[
401,
23,
460
]
],
[
[
1523,
63,
999
],
[
999,
23,
460
]
],
[
[
1523,
40,
954
],
[
954,
... | [
[
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
... | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylpera... |
DB06810 | DB12364 | 397 | 1,421 | [
"DDInter1484",
"DDInter200"
] | Plicamycin | Betrixaban | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
397,
25,
1421
]
],
[
[
397,
23,
944
],
[
944,
62,
1421
]
],
[
[
397,
23,
539
],
[
539,
23,
1421
]
],
[
[
397,
63,
529
],
[
529,
... | [
[
[
"Plicamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Plicamycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Plicamycin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Plicamycin may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cau... |
DB00390 | DB09074 | 1,252 | 1,362 | [
"DDInter554",
"DDInter1327"
] | Digoxin | Olaparib | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
1252,
24,
1362
]
],
[
[
1252,
24,
1478
],
[
1478,
24,
1362
]
],
[
[
1252,
63,
552
],
[
552,
24,
1362
]
],
[
[
1252,
24,
214
],
[
214,
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivac... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may c... |
DB01105 | DB01233 | 222 | 1,311 | [
"DDInter1665",
"DDInter1197"
] | Sibutramine | Metoclopramide | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
222,
24,
1311
]
],
[
[
222,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
222,
63,
817
],
[
817,
23,
1311
]
],
[
[
222,
63,
1020
],
[
1020,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Sibutramine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect)... | Sibutramine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine may cause a minor interaction that can limit clinical effects when taken with Metoc... |
DB00533 | DB00563 | 1,416 | 663 | [
"DDInter1613",
"DDInter1174"
] | Rofecoxib | Methotrexate | Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene m... | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Moderate | 1 | [
[
[
1416,
24,
663
]
],
[
[
1416,
24,
126
],
[
126,
62,
663
]
],
[
[
1416,
63,
91
],
[
91,
24,
663
]
],
[
[
1416,
24,
891
],
[
891,
6... | [
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
]
],
[
[
"Rofecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Methotrexate
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin m... |
DB00747 | DB04843 | 1,442 | 1,511 | [
"DDInter1647",
"DDInter1149"
] | Scopolamine | Mepenzolate | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1442,
24,
1511
]
],
[
[
1442,
64,
675
],
[
675,
24,
1511
]
],
[
[
1442,
24,
537
],
[
537,
24,
1511
]
],
[
[
1442,
63,
194
],
[
194,
... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Scopolamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
... | Scopolamine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyc... |
DB00261 | DB12364 | 702 | 1,421 | [
"DDInter93",
"DDInter200"
] | Anagrelide | Betrixaban | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
702,
25,
1421
]
],
[
[
702,
23,
297
],
[
297,
23,
1421
]
],
[
[
702,
23,
944
],
[
944,
62,
1421
]
],
[
[
702,
63,
529
],
[
529,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Anagrelide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u... | Anagrelide may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Betrixaban
Anagrelide may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a m... |
DB00472 | DB04868 | 758 | 478 | [
"DDInter758",
"DDInter1293"
] | Fluoxetine | Nilotinib | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Major | 2 | [
[
[
758,
25,
478
]
],
[
[
758,
24,
1468
],
[
1468,
63,
478
]
],
[
[
758,
6,
6017
],
[
6017,
45,
478
]
],
[
[
758,
7,
3727
],
[
3727,
... | [
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
]
],
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
... | Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Fluoxetine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Fluoxetine (Compound) ... |
DB09291 | DB11691 | 741 | 1,499 | [
"DDInter1615",
"DDInter1258"
] | Rolapitant | Naldemedine | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
741,
24,
1499
]
],
[
[
741,
63,
307
],
[
307,
23,
1499
]
],
[
[
741,
64,
1670
],
[
1670,
24,
1499
]
],
[
[
741,
25,
1339
],
[
1339,
... | [
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Rolapitant may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause a m... |
DB00647 | DB11110 | 675 | 603 | [
"DDInter528",
"DDInter1115"
] | Dextropropoxyphene | Magnesium citrate | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
675,
24,
603
]
],
[
[
675,
25,
57
],
[
57,
24,
603
]
],
[
[
675,
24,
1616
],
[
1616,
24,
603
]
],
[
[
675,
40,
494
],
[
494,
24,... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
... | Dextropropoxyphene may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with H... |
DB01021 | DB01168 | 674 | 1,053 | [
"DDInter1861",
"DDInter1526"
] | Trichlormethiazide | Procarbazine | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
674,
24,
1053
]
],
[
[
674,
24,
848
],
[
848,
40,
1053
]
],
[
[
674,
18,
4360
],
[
4360,
57,
1053
]
],
[
[
674,
62,
126
],
[
126,
... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen... | Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen (Compound) resembles Procarbazine (Compound)
Trichlormethiazide (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Procarbazine (Compound)
Trichlormethiazide may cause a min... |
DB00176 | DB00603 | 529 | 303 | [
"DDInter770",
"DDInter1137"
] | Fluvoxamine | Medroxyprogesterone acetate | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Moderate | 1 | [
[
[
529,
24,
303
]
],
[
[
529,
24,
167
],
[
167,
1,
303
]
],
[
[
529,
6,
8374
],
[
8374,
45,
303
]
],
[
[
529,
21,
28956
],
[
28956,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acetate"
]
],
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocor... | Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Medroxyprogesterone acetate (Compound)
Fluvoxamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Medroxyprogesterone acetate (Compound)
Fluvoxamine (Compound)... |
DB00005 | DB11730 | 1,057 | 351 | [
"DDInter687",
"DDInter1588"
] | Etanercept | Ribociclib | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1057,
25,
351
]
],
[
[
1057,
24,
112
],
[
112,
23,
351
]
],
[
[
1057,
25,
310
],
[
310,
24,
351
]
],
[
[
1057,
24,
597
],
[
597,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Etanercept may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may ... |
DB08865 | DB12674 | 1,593 | 975 | [
"DDInter448",
"DDInter1105"
] | Crizotinib | Lurbinectedin | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Major | 2 | [
[
[
1593,
25,
975
]
],
[
[
1593,
63,
1488
],
[
1488,
24,
975
]
],
[
[
1593,
24,
1613
],
[
1613,
24,
975
]
],
[
[
1593,
24,
159
],
[
159,
... | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
"Fludar... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon be... |
DB00013 | DB00055 | 1,255 | 834 | [
"DDInter1905",
"DDInter605"
] | Urokinase | Drotrecogin alfa | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Major | 2 | [
[
[
1255,
25,
834
]
],
[
[
1255,
23,
539
],
[
539,
62,
834
]
],
[
[
1255,
24,
318
],
[
318,
63,
834
]
],
[
[
1255,
25,
1226
],
[
1226,
... | [
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",... | Urokinase may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Drotrecogin alfa
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalo... |
DB00372 | DB00413 | 999 | 1,346 | [
"DDInter1793",
"DDInter1505"
] | Thiethylperazine | Pramipexole | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is one of the m... | Moderate | 1 | [
[
[
999,
24,
1346
]
],
[
[
999,
24,
272
],
[
272,
63,
1346
]
],
[
[
999,
63,
701
],
[
701,
24,
1346
]
],
[
[
999,
25,
1311
],
[
1311,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramipexole"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorphenirami... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Pramipexole
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB06176 | DB12095 | 1,342 | 179 | [
"DDInter1616",
"DDInter1760"
] | Romidepsin | Telotristat ethyl | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
1342,
24,
179
]
],
[
[
1342,
63,
79
],
[
79,
24,
179
]
],
[
[
1342,
64,
1493
],
[
1493,
24,
179
]
],
[
[
1342,
24,
214
],
[
214,
... | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Romidepsin may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine m... |
DB00414 | DB08870 | 590 | 850 | [
"DDInter16",
"DDInter228"
] | Acetohexamide | Brentuximab vedotin | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Moderate | 1 | [
[
[
590,
24,
850
]
],
[
[
590,
24,
1338
],
[
1338,
24,
850
]
],
[
[
590,
24,
1033
],
[
1033,
63,
850
]
],
[
[
590,
63,
989
],
[
989,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when tak... |
DB00529 | DB00877 | 789 | 629 | [
"DDInter779",
"DDInter1678"
] | Foscarnet | Sirolimus | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Major | 2 | [
[
[
789,
25,
629
]
],
[
[
789,
21,
29203
],
[
29203,
60,
629
]
],
[
[
789,
63,
1215
],
[
1215,
24,
629
]
],
[
[
789,
24,
167
],
[
167,
... | [
[
[
"Foscarnet",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
]
],
[
[
"Foscarnet",
"{u} (Compound) causes {v} (Side Effect)",
"Aspartate aminotransferase increased"
],
[
"Aspartate aminotransferase increase... | Foscarnet (Compound) causes Aspartate aminotransferase increased (Side Effect) and Aspartate aminotransferase increased (Side Effect) is caused by Sirolimus (Compound)
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a moderate interaction... |
DB00180 | DB09054 | 1,351 | 384 | [
"DDInter749",
"DDInter905"
] | Flunisolide | Idelalisib | Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1351,
24,
384
]
],
[
[
1351,
40,
891
],
[
891,
24,
384
]
],
[
[
1351,
24,
851
],
[
851,
24,
384
]
],
[
[
1351,
23,
659
],
[
659,
... | [
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Flunisolide",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a m... | Flunisolide (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone may cause a moderate interaction that... |
DB00909 | DB06691 | 306 | 849 | [
"DDInter1971",
"DDInter1155"
] | Zonisamide | Mepyramine | Zonisamide is a sulfonamide anticonvulsant used as an adjunctive therapy in adults with partial-onset seizures.[L42530,L42535] Zonisamide may act by blocking repetitive firing of voltage-gated sodium channels, leading to a reduction of T-type calcium channel currents or by binding allosterically to GABA receptors. This... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Major | 2 | [
[
[
306,
25,
849
]
],
[
[
306,
64,
1594
],
[
1594,
24,
849
]
],
[
[
306,
25,
272
],
[
272,
24,
849
]
],
[
[
306,
24,
770
],
[
770,
2... | [
[
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mepyramine"
]
],
[
[
"Zonisamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} m... | Zonisamide may lead to a major life threatening interaction when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Zonisamide may lead to a major life threatening interaction when taken with Chlorpheniramine and Chlorpheniramine may cause a m... |
DB00424 | DB01591 | 19 | 667 | [
"DDInter896",
"DDInter1696"
] | Hyoscyamine | Solifenacin | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
19,
24,
667
]
],
[
[
19,
6,
7420
],
[
7420,
45,
667
]
],
[
[
19,
21,
28743
],
[
28743,
60,
667
]
],
[
[
19,
24,
830
],
[
830,
63... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) binds {v} (Gene)",
"CHRM4"
],
[
"CHRM4",
"{u} (Gene) is bound by {v} (Compound)"... | Hyoscyamine (Compound) binds CHRM4 (Gene) and CHRM4 (Gene) is bound by Solifenacin (Compound)
Hyoscyamine (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Solifenacin (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00346 | DB00757 | 472 | 1,166 | [
"DDInter44",
"DDInter581"
] | Alfuzosin | Dolasetron | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
472,
25,
1166
]
],
[
[
472,
6,
8374
],
[
8374,
45,
1166
]
],
[
[
472,
21,
29081
],
[
29081,
60,
1166
]
],
[
[
472,
23,
752
],
[
752,
... | [
[
[
"Alfuzosin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Alfuzosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dolasetro... | Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dolasetron (Compound)
Alfuzosin (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Dolasetron (Compound)
Alfuzosin may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetid... |
DB01265 | DB12834 | 1,477 | 148 | [
"DDInter1757",
"DDInter1649"
] | Telbivudine | Secnidazole | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
1477,
24,
148
]
],
[
[
1477,
24,
1593
],
[
1593,
24,
148
]
],
[
[
1477,
63,
597
],
[
597,
24,
148
]
],
[
[
1477,
64,
491
],
[
491,
... | [
[
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[... | Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol an... |
DB00213 | DB11963 | 837 | 1,045 | [
"DDInter1388",
"DDInter465"
] | Pantoprazole | Dacomitinib | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was devel... | Major | 2 | [
[
[
837,
25,
1045
]
],
[
[
837,
63,
80
],
[
80,
24,
1045
]
],
[
[
837,
23,
109
],
[
109,
24,
1045
]
],
[
[
837,
24,
883
],
[
883,
24... | [
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacomitinib"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphetamine"
],
[
"Amph... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Pantoprazole may cause a minor interaction that can limit clinical effects when taken with Duloxetine and D... |
DB01246 | DB06016 | 820 | 1,508 | [
"DDInter45",
"DDInter300"
] | Alimemazine | Cariprazine | A phenothiazine derivative that is used as an antipruritic. | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Moderate | 1 | [
[
[
820,
24,
1508
]
],
[
[
820,
24,
1637
],
[
1637,
24,
1508
]
],
[
[
820,
25,
1593
],
[
1593,
63,
1508
]
],
[
[
820,
63,
1242
],
[
1242,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cariprazine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
],
... | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite and Amyl Nitrite may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Alimemazine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may... |
DB00747 | DB00748 | 1,442 | 662 | [
"DDInter1647",
"DDInter297"
] | Scopolamine | Carbinoxamine | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
1442,
24,
662
]
],
[
[
1442,
63,
1594
],
[
1594,
24,
662
]
],
[
[
1442,
21,
28921
],
[
28921,
60,
662
]
],
[
[
1442,
24,
1429
],
[
142... | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Scopolamine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Carbinoxamine... |
DB00726 | DB00748 | 1,164 | 662 | [
"DDInter1876",
"DDInter297"
] | Trimipramine | Carbinoxamine | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
1164,
24,
662
]
],
[
[
1164,
63,
1594
],
[
1594,
24,
662
]
],
[
[
1164,
1,
216
],
[
216,
24,
662
]
],
[
[
1164,
1,
11439
],
[
11439,
... | [
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Trimipramine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interac... |
DB11837 | DB12245 | 1,297 | 823 | [
"DDInter1351",
"DDInter1863"
] | Osilodrostat | Triclabendazole | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
1297,
24,
823
]
],
[
[
1297,
62,
1247
],
[
1247,
23,
823
]
],
[
[
1297,
63,
1612
],
[
1612,
24,
823
]
],
[
[
1297,
64,
1622
],
[
1622,... | [
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Osilodrostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
... | Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Fost... |
DB00468 | DB01319 | 1,424 | 34 | [
"DDInter1557",
"DDInter777"
] | Quinine | Fosamprenavir | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
1424,
24,
34
]
],
[
[
1424,
24,
1091
],
[
1091,
40,
34
]
],
[
[
1424,
6,
8374
],
[
8374,
45,
34
]
],
[
[
1424,
21,
29062
],
[
29062,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Quinine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Quinine (Compound) causes Neutropenia (Side Effect) and Neutropeni... |
DB00063 | DB01009 | 366 | 935 | [
"DDInter659",
"DDInter1009"
] | Eptifibatide | Ketoprofen | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Moderate | 1 | [
[
[
366,
24,
935
]
],
[
[
366,
24,
1274
],
[
1274,
24,
935
]
],
[
[
366,
24,
886
],
[
886,
1,
935
]
],
[
[
366,
25,
702
],
[
702,
24... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and... |
DB00280 | DB00604 | 494 | 1,425 | [
"DDInter575",
"DDInter385"
] | Disopyramide | Cisapride | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. | Major | 2 | [
[
[
494,
25,
1425
]
],
[
[
494,
24,
1311
],
[
1311,
1,
1425
]
],
[
[
494,
6,
8374
],
[
8374,
45,
1425
]
],
[
[
494,
23,
112
],
[
112,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Met... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Cisapride (Compound)
Disopyramide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cisapride (Compound)
Disopyramide may cause a minor interaction that can limi... |
DB11703 | DB11979 | 405 | 1,320 | [
"DDInter9",
"DDInter625"
] | Acalabrutinib | Elagolix | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
405,
24,
1320
]
],
[
[
405,
24,
1297
],
[
1297,
24,
1320
]
],
[
[
405,
63,
1427
],
[
1427,
24,
1320
]
],
[
[
405,
64,
129
],
[
129,
... | [
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
... | Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Elagolix
Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine ... |
DB08875 | DB11703 | 1,618 | 405 | [
"DDInter262",
"DDInter9"
] | Cabozantinib | Acalabrutinib | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1618,
25,
405
]
],
[
[
1618,
63,
1051
],
[
1051,
24,
405
]
],
[
[
1618,
64,
690
],
[
690,
24,
405
]
],
[
[
1618,
25,
982
],
[
982,
... | [
[
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
... | Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Cabozantinib may lead to a major life threatening interaction when taken with Rifabutin and R... |
DB00046 | DB00959 | 1,179 | 1,486 | [
"DDInter940",
"DDInter1191"
] | Insulin lispro | Methylprednisolone | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
1179,
24,
1486
]
],
[
[
1179,
24,
175
],
[
175,
40,
1486
]
],
[
[
1179,
24,
167
],
[
167,
1,
1486
]
],
[
[
1179,
24,
1072
],
[
1072,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolo... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) re... |
DB04575 | DB09564 | 35 | 1,296 | [
"DDInter1555",
"DDInter930"
] | Quinestrol | Insulin degludec | The 3-cyclopentyl ether of ethinyl estradiol. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
35,
24,
1296
]
],
[
[
35,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
35,
24,
761
],
[
761,
24,
1296
]
],
[
[
35,
40,
380
],
[
380,
24... | [
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin a... |
DB00364 | DB06723 | 417 | 115 | [
"DDInter1717",
"DDInter58"
] | Sucralfate | Aluminum hydroxide | Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia. It is considered a _cytoprotective agent_, protect... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
417,
24,
115
]
],
[
[
417,
21,
29803
],
[
29803,
60,
115
]
],
[
[
417,
24,
1482
],
[
1482,
23,
115
]
],
[
[
417,
23,
461
],
[
461,
... | [
[
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Sucralfate",
"{u} (Compound) causes {v} (Side Effect)",
"Venous thrombosis"
],
[
"Venous thrombosis",
"{... | Sucralfate (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Aluminum hydroxide (Compound)
Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects whe... |
DB00687 | DB00819 | 870 | 471 | [
"DDInter747",
"DDInter15"
] | Fludrocortisone | Acetazolamide | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Moderate | 1 | [
[
[
870,
24,
471
]
],
[
[
870,
24,
997
],
[
997,
40,
471
]
],
[
[
870,
21,
29232
],
[
29232,
60,
471
]
],
[
[
870,
63,
245
],
[
245,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Fludrocortisone (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Acetazolamide (Compound)
Fludrocortisone may ca... |
DB04953 | DB06691 | 495 | 849 | [
"DDInter708",
"DDInter1155"
] | Ezogabine | Mepyramine | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
495,
24,
849
]
],
[
[
495,
63,
1594
],
[
1594,
24,
849
]
],
[
[
495,
24,
407
],
[
407,
63,
849
]
],
[
[
495,
24,
516
],
[
516,
2... | [
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cau... |
DB00087 | DB08901 | 599 | 1,468 | [
"DDInter41",
"DDInter1492"
] | Alemtuzumab | Ponatinib | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
599,
24,
1468
]
],
[
[
599,
24,
478
],
[
478,
24,
1468
]
],
[
[
599,
24,
987
],
[
987,
63,
1468
]
],
[
[
599,
63,
268
],
[
268,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 10... |
DB00295 | DB11130 | 475 | 407 | [
"DDInter1244",
"DDInter1344"
] | Morphine | Opium | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
475,
24,
407
]
],
[
[
475,
24,
409
],
[
409,
24,
407
]
],
[
[
475,
25,
558
],
[
558,
24,
407
]
],
[
[
475,
63,
529
],
[
529,
24,... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Felodipine"
],
[
"Felo... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Morphine may lead to a major life threatening interaction when taken with Zolpidem and Zolpidem may cause a moderate in... |
DB00674 | DB00757 | 1,516 | 1,166 | [
"DDInter802",
"DDInter581"
] | Galantamine | Dolasetron | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Moderate | 1 | [
[
[
1516,
24,
1166
]
],
[
[
1516,
63,
19
],
[
19,
40,
1166
]
],
[
[
1516,
63,
85
],
[
85,
1,
1166
]
],
[
[
1516,
6,
12523
],
[
12523,
... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dolasetron"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[... | Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Dolasetron (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Dolasetron (Compound)
... |
DB00682 | DB06822 | 126 | 802 | [
"DDInter1951",
"DDInter1812"
] | Warfarin | Tinzaparin | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Major | 2 | [
[
[
126,
25,
802
]
],
[
[
126,
23,
944
],
[
944,
62,
802
]
],
[
[
126,
24,
222
],
[
222,
24,
802
]
],
[
[
126,
63,
758
],
[
758,
24,... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tinzaparin"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Tinzaparin
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may... |
DB00631 | DB00853 | 372 | 1,686 | [
"DDInter405",
"DDInter1762"
] | Clofarabine | Temozolomide | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Moderate | 1 | [
[
[
372,
24,
1686
]
],
[
[
372,
21,
28996
],
[
28996,
60,
1686
]
],
[
[
372,
23,
945
],
[
945,
62,
1686
]
],
[
[
372,
62,
1467
],
[
1467,
... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
]
],
[
[
"Clofarabine",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal discomfort"
],
[
"Musculoskeletal discomf... | Clofarabine (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Temozolomide (Compound)
Clofarabine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit cl... |
DB00771 | DB09488 | 262 | 103 | [
"DDInter397",
"DDInter23"
] | Clidinium | Acrivastine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
262,
24,
103
]
],
[
[
262,
24,
1405
],
[
1405,
24,
103
]
],
[
[
262,
63,
85
],
[
85,
24,
103
]
],
[
[
262,
74,
194
],
[
194,
24,... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Acrivastine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Atropine and... |
DB00006 | DB11689 | 942 | 321 | [
"DDInter217",
"DDInter1659"
] | Bivalirudin | Selumetinib | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important t... | Activation of the Raf-MEK-ERK signalling pathway is known to be implemented in several types of malignancies; thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway. Results from clinical trials investigating ea... | Moderate | 1 | [
[
[
942,
24,
321
]
],
[
[
942,
24,
298
],
[
298,
24,
321
]
],
[
[
942,
25,
291
],
[
291,
24,
321
]
],
[
[
942,
25,
1421
],
[
1421,
6... | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Selumetinib"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
],
[
... | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Protein C and Protein C may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib
Bivalirudin may lead to a major life threatening interaction when taken with Argatroban and Argatroban may cause... |
DB00472 | DB09330 | 758 | 985 | [
"DDInter758",
"DDInter1352"
] | Fluoxetine | Osimertinib | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
758,
25,
985
]
],
[
[
758,
23,
112
],
[
112,
23,
985
]
],
[
[
758,
24,
480
],
[
480,
24,
985
]
],
[
[
758,
24,
657
],
[
657,
63,... | [
[
[
"Fluoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Fluoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronid... | Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and For... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.